Results 181 to 190 of about 1,067,036 (373)

If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndrome

Annals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives Intravenous immunoglobulin (IVIg) is an effective treatment for Guillain–Barré syndrome (GBS), but recovery varies between patients. This study aims to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of a single and a second IVIg dose (SID) in patients with GBS.
Sander J. van Tilburg, Ruth Huizinga, Krista Kuitwaard, Sebastiaan D.T. Sassen, Christa Walgaard, Pieter A. van Doorn, Bart C. Jacobs, Birgit C.P Koch   +7 more
wiley   +1 more source

Congenital, sporadic dysgammaglobulinaemia (absence of IgA and partial deficit in IgG and IgM) [PDF]

, 1969
L. A. Scuro, S Todesco, G Previato, B Pernis   +3 more
openalex   +1 more source

Clinical impact and safety of brain biopsy in unexplained central nervous system disorders: a real‐world cohort study

Annals of Clinical and Translational Neurology, EarlyView.
Abstract Objective A substantial part of central nervous system (CNS) disorders remains unexplained, despite various new and minimally invasive diagnostic techniques. Within this rapidly developing diagnostic field, the precise role of brain biopsy is unknown.
Robin W. van Steenhoven, Saan Salih, Juna M. de Vries, Ide Smets, Rob M. Verdijk, Mayke Gardeniers, Jeroen Kerstens, Juliette Brenner, Yvette S. Crijnen, Marjolein Geurts, Jacoline E. C. Bromberg, Corine H. GeurtsvanKessel, Peter A. E. Sillevis Smitt, Rutger K. Balvers, Maarten J. Titulaer   +14 more
wiley   +1 more source

Neuromielitis óptica: Estado del arte

Salud Uninorte, 2007
La neuromielitis óptica es una enfermedad desmielinizante idiopática, severa, del sistema nervioso central que afecta principalmente el nervio óptico y la médula espinal.
Jorge Daza Barriga, Angélica Roncallo Del Portillo   +1 more
doaj  

The Immunosuppressive Effect of Passively Administered Antibody IgG Fragments [PDF]

, 1969
Jean‐Charles Cerottini, Patricia J. McConahey, Frank J. Dixon   +2 more
openalex   +1 more source

High‐Throughput Immunoassays for Cavin‐4 IgG: A Diagnostic Tool for Immune‐Mediated Rippling Muscle Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACTCavin‐4 was identified as a potential autoantigen for immune‐mediated rippling muscle disease (iRMD). To validate this, we developed and tested various immunoassays, including a cell‐based assay (CBA), cavin‐4 recombinant protein ELISA, and multi‐peptide ELISA. Among 19 iRMD patients, all exhibited muscle rippling, and 13 had percussion‐induced
Reghann G. LaFrance‐Corey, Haidara Kherbek, Nimalan Harinesan, Margherita Milone, Naveen K. Paramasivan, Pallab Sarker, Andrew M. Knight, Carley Karsten, Surendra Dasari, Teerin Liewluck, William J. Litchy, Sean J. Pittock, John R. Mills, Divyanshu Dubey   +13 more
wiley   +1 more source

IgG myeloma in cerebrospinal fluid with a total protein of 32 mg.-100 ml. [PDF]

, 1967
K. Gavrilescu, A Papakrivopoulos
openalex   +1 more source

Epitope Mapping of Anti‐Neurofascin 155 Antibody in a Large Cohort of Autoimmune Nodopathy Patients

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune nodopathy (AN), a newly recognized disease entity, is an immune‐mediated polyneuropathy involving autoantibodies against cell adhesion molecules located in nodes of Ranvier and paranodal regions, such as neurofascin 186 (NF186) and neurofascin 155 (NF155). The present study aimed to identify the epitopes for autoantibodies
Amina A. Abdelhadi, Hidenori Ogata, Xu Zhang, Takumi Tashiro, Ryo Yamasaki, Jun‐ichi Kira, Noriko Isobe   +6 more
wiley   +1 more source

Reaction of Dissociated IgM Anti-γ-Globulins with Rabbit Immunoglobulin G (IgG) [PDF]

, 1967
Ralph E. Schrohenloher
openalex   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source